Cerity Partners LLC Has $29.52 Million Stock Position in GE HealthCare Technologies Inc. $GEHC

Cerity Partners LLC lessened its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 359,951 shares of the company’s stock after selling 13,619 shares during the period. Cerity Partners LLC’s holdings in GE HealthCare Technologies were worth $29,523,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of GEHC. Empowered Funds LLC lifted its holdings in shares of GE HealthCare Technologies by 6.1% during the first quarter. Empowered Funds LLC now owns 28,848 shares of the company’s stock worth $2,328,000 after purchasing an additional 1,665 shares during the period. Acadian Asset Management LLC acquired a new position in shares of GE HealthCare Technologies during the first quarter worth $259,000. Cresset Asset Management LLC lifted its holdings in shares of GE HealthCare Technologies by 12.5% during the second quarter. Cresset Asset Management LLC now owns 7,802 shares of the company’s stock worth $578,000 after purchasing an additional 865 shares during the period. Jump Financial LLC lifted its holdings in shares of GE HealthCare Technologies by 317.6% during the second quarter. Jump Financial LLC now owns 28,132 shares of the company’s stock worth $2,084,000 after purchasing an additional 21,396 shares during the period. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of GE HealthCare Technologies by 8.6% during the second quarter. Gamco Investors INC. ET AL now owns 4,041 shares of the company’s stock worth $299,000 after purchasing an additional 320 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at GE HealthCare Technologies

In related news, Director Rodney F. Hochman purchased 1,618 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was purchased at an average cost of $62.03 per share, with a total value of $100,364.54. Following the completion of the purchase, the director owned 1,618 shares in the company, valued at approximately $100,364.54. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Lobo purchased 10,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was bought at an average cost of $64.18 per share, with a total value of $641,800.00. Following the completion of the purchase, the director owned 14,363 shares of the company’s stock, valued at approximately $921,817.34. This represents a 229.20% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 21,847 shares of company stock valued at $1,361,355. 0.36% of the stock is owned by insiders.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC opened at $63.76 on Thursday. GE HealthCare Technologies Inc. has a twelve month low of $58.75 and a twelve month high of $89.77. The firm has a fifty day simple moving average of $66.59 and a 200 day simple moving average of $75.36. The company has a market capitalization of $29.00 billion, a PE ratio of 15.25, a P/E/G ratio of 1.49 and a beta of 0.74. The company has a quick ratio of 0.95, a current ratio of 1.22 and a debt-to-equity ratio of 0.95.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Wednesday, April 29th. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The firm had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the prior year, the business earned $1.01 EPS. GE HealthCare Technologies’s quarterly revenue was up 7.4% on a year-over-year basis. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, sell-side analysts forecast that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GEHC. Stifel Nicolaus set a $80.00 price target on shares of GE HealthCare Technologies in a report on Wednesday, April 29th. The Goldman Sachs Group reiterated a “neutral” rating on shares of GE HealthCare Technologies in a report on Monday. HSBC cut their price target on shares of GE HealthCare Technologies from $100.00 to $90.00 in a report on Thursday, April 30th. Jefferies Financial Group cut their price target on shares of GE HealthCare Technologies from $105.00 to $90.00 in a report on Thursday, April 30th. Finally, Evercore set a $80.00 price target on shares of GE HealthCare Technologies in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $80.21.

GE HealthCare Technologies Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.